estrogens, esterified
Trade name: menrium component estrogens, esterified
Approved
Jul 28, 1966
Esterified estrogens (EEs), sold under the brand names Estratab and Menest among others, is an estrogen medication which is used hormone therapy for menopausal symptoms and low sex hormone levels in women, to treat breast cancer in both women and men, and to treat prostate cancer in men. It is formulated alone or in combination with methyltestosterone. It is taken by mouth. — Wikipedia
Clinical trial activity
5 trials · 3 clinical orgs · 6 marketing orgs
Earliest trial started Mar 1, 2004 (NCT00131924)
Timeline
1960s
1970s
- Apr 20, 1977
Mylan — Marketing Organization
- Jun 17, 1977
Solvay — Marketing Organization
- Sep 28, 1977
Monarch Pharmaceuticals — Marketing Organization
2000s
- Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Estrogen receptorAGONIST
ESR1 agonist
Combination products
menrium
with chlordiazepoxide
Approval history
- approvedJul 28, 1966
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaEsterified estrogens ↗
- NCATS3ASP8Q3768 ↗
- ChEMBLCHEMBL1201468 ↗
Also known as
- amnestrogen
- amnestrogen
- esterified estrogens
- esterified estrogens
- esterified estrogens
- estratab
- estratab
- estrogens,esterified
- estrogens,esterified
- estrogens, esterified
- estrogens, esterified
- estrogens, esterified
- estrogens, esterified
- estrogens, esterified component of menrium
- femogen
- femogen
- menrium component estrogens, esterified
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00160342 | Phase 2 | Jun 1, 2005 | Solvay |
| NCT00141544 | Phase 2 | Jul 1, 2004 | Solvay |
| NCT00141557 | Phase 2 | Jul 1, 2004 | Solvay |
| NCT00141570 | Phase 2 | Jun 1, 2004 | Solvay |
| NCT00131924 | Phase 2 | Mar 1, 2004 | National Cancer Institute (NCI), Northwestern University |
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Solvay | For profit | 4 | 4 | 1 | 2004 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2004 |
| Northwestern University | Academic/Hospital | 1 | 1 | 1 | 2004 |
Marketing (8)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Bristol-Myers Squibb | For profit | MKTG | — |
| Monarch Pharmaceuticals | For profit | MKTG | Sep 28, 1977 |
| Mylan | For profit | MKTG | Apr 20, 1977 |
| Roche | For profit | MKTG | Jul 28, 1966 |
| Roche | For profit | SYN | Sep 28, 1977 |
| Roche | For profit | NDA | Jul 28, 1966 |
| Sandoz | For profit | MKTG | — |
| Solvay | For profit | MKTG | Jun 17, 1977 |